Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company focused on the development of protein kinase inhibitor therapeutics for Parkinson's disease ("PD"), related disorders, and other conditions involving Abelson Tyrosine Kinases, has announced a significant stride in its endeavors. The company has successfully devised an innovative tablet formulation for IkT-148009, aimed at enhancing drug exposure and addressing prevailing obstacles associated with patient administration.

Dr. Milton Werner, the President & CEO of Inhibikase, highlighted the company's progress, stating, "As we make headway with our 201 trial, investigating risvodetinib across 50, 100, and 200 mg doses for Parkinson's disease, our efforts encompass advancing our formulation and delivery capabilities. Recently, we accomplished the characterization of an inventive tablet formulation, aligning with the oral form that demonstrated efficacy in validated animal models of Parkinson's disease. This pioneering tablet formulation remarkably augments drug exposure at steady-state, using the same risvodetinib dosage. This enhancement holds the potential to facilitate therapeutic efficacy with a lower dose, thus potentially bolstering safety and tolerability of risvodetinib. Moreover, the reduced size of these tablets compared to the currently employed capsules in the ongoing 201 clinical trial might help individuals facing challenges in swallowing oral medication due to their medical condition. This groundbreaking tablet formulation is anticipated to be implemented in the forthcoming 12-month extension of the 201 trial."

Inhibikase's commitment to refining drug delivery mechanisms and ensuring patient comfort remains a driving force behind their pursuit of improved treatment for Parkinson's disease and associated disorders.

Source: prnewswire.com